Participants 48 95 5
hormone-resistant metastatic prostate carcinoma
Participants 146 303 7
51 patients with stage D hormone-resistant prostatic carcinoma, comparing a combination of doxorubicin and lomustine (DC) with cyclophosphamide and 5-FU (CF)
Participants 1184 1219 3
an essentially geriatric population
